Connoa -B (02162.HK): CM512 has been included in the list of breakthrough therapeutic products by the Drug Evaluation Center of the National Medical Products Administration.

Intelligence Finance APP News, Konnua-B (02162.HK) announced that the company's key research and development product CM512 (TSLP/IL-13 bispecific antibody) has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration Drug Evaluation Center for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).